Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marissa Duplaga

Nurse Practitioner, Family Glen Dale, WV Nurse Practitioner

NPI 1871060343 CMS profile 10621454

1612 Wheeling Ave, Glen Dale, WV 26038

Open in the dashboard

General payments

$5,528

329 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marissa Duplaga of Glen Dale, WV is reported in the CMS Open Payments database as having received $5,528 across 329 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $514 30
2024 General $1,289 71
2023 General $1,581 97
2022 General $1,299 78
2021 General $845 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marissa Duplaga
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Marissa Duplaga were reported at $514. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Marissa Duplaga Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $845 $124 $35–$379 $132
2022 $1,299 $141 $44–$430 $149
2023 $1,581 $154 $49–$476 $160
2024 $1,289 $165 $51–$504 $164
2025 $514 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $882 53 payments
  2. Lilly USA, LLC $594 33 payments
  3. AstraZeneca Pharmaceuticals LP $499 31 payments
  4. Pfizer Inc. $410 25 payments
  5. Kowa Pharmaceuticals America, Inc. $410 32 payments
  6. AbbVie, Inc. $352 18 payments
  7. Merck Sharp & Dohme Corporation $309 16 payments
  8. Janssen Pharmaceuticals, Inc $286 19 payments
  9. Astellas Pharma US Inc $227 12 payments
  10. Sanofi-Aventis U.S. LLC $224 15 payments
  11. Other $1,333 75 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,528 329 payments
Products named General payments · program years 2021–2025
  1. Ozempic $767 46 payments
  2. RYBELSUS $702 42 payments
  3. MOUNJARO $323 18 payments
  4. BRILINTA $307 18 payments
  5. XARELTO $286 19 payments
  6. JARDIANCE $255 14 payments
  7. ELIQUIS $227 15 payments
  8. TRULICITY $222 13 payments
  9. Kerendia $216 13 payments
  10. Veozah $208 11 payments
  11. Other $4,782 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

3,103

Median for Nurse Practitioner: 389

Drug cost

$302,865

Median for Nurse Practitioner: $21,885

Branded share of claims

20.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 61 $66,403
Ozempic Semaglutide Brand 36 $59,630
Jardiance Empagliflozin Brand 34 $37,590
Rybelsus Semaglutide Brand 25 $29,258
Eliquis Apixaban Brand 18 $21,687
Farxiga Dapagliflozin Propanediol Brand 18 $18,463
Glyxambi Empagliflozin/Linagliptin Brand 13 $11,411
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $9,474
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $7,053
Myrbetriq Mirabegron Brand 14 $7,031

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$70,886

Of which drugs: $4,265

Medicare patients

307

Average age 75

Services billed

5,501

158 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 32%
Chronic kidney disease 27%
Ischemic heart disease 25%
Depression 25%
Cancer 16%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 22 22 $1,780
Injection, methylprednisolone acetate, 1 mg J1010 Office 65 3,081 $299
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 89 402 $257
Injection, ketorolac tromethamine, per 15 mg J1885 Office 43 212 $102
Injection, methylprednisolone acetate, 40 mg J1030 Office 28 29 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRILINTA
  • AstraZeneca Pharmaceuticals LP $119
$119 — —
Veozah
  • Astellas Pharma US Inc $113
$113 — —
RYBELSUS
  • Novo Nordisk Inc $112
$112 25 —
Ozempic
  • Novo Nordisk Inc $112
$112 36 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record